Thiakis enjoys rights to an extensive number of patents and patent applications, claiming both methods of treating obesity and novel peptide compositions. The obesity market is truly global; patent filings are therefore designated for extensive coverage.

The company is the exclusive licensee of multiple patent families from Imperial Innovations and OHSU directed to the methods of treating obesity and related co-morbidities using PYY3-36 and oxyntomodulin, analogues of the peptides, combinations thereof, and their use in conjunction with GLP-1 agonists.

Furthermore, Thiakis has exclusively licensed patent families from Imperial Innovations claiming the compositions of multiple novel analogues of oxyntomodulin that demonstrate enhanced potency and efficacy in comparison to the native peptide, and their use for the treatment of obesity.